paclitaxel + cyclophosphamide + dexamethasone

This combination therapy, consisting of paclitaxel, cyclophosphamide, and dexamethasone, is being evaluated by Sun Yat-sen University for the treatment of relapsed or refractory multiple myeloma. Paclitaxel is a taxane that stabilizes microtubules, interfering with cell division and inducing cell cycle arrest. Cyclophosphamide is an alkylating agent that causes DNA cross-linking, leading to DNA damage and apoptosis. Dexamethasone is a potent corticosteroid that acts as a glucocorticoid receptor agonist, inducing apoptosis in plasma cells and providing anti-inflammatory effects. This specific regimen (PCD) is being investigated in Phase 2 clinical trials in China as a salvage therapy for patients who have failed standard treatments for multiple myeloma.

Other names

PCD regimen